cancers-logo

Journal Browser

Journal Browser

Lung Cancer—Molecular Insights and Targeted Therapies (Third Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 971

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Biomedicine of Seville (IBIS) (HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain
Interests: lung cancer; biomarkers; genetics; diagnosis; prognosis; targeted therapies; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Special Issue is the third edition of the Special Issue. You can find the first edition here: Lung Cancer—Molecular Insights and Targeted Therapies (https://www.mdpi.com/journal/cancers/special_issues/LCMITT), and the second one here: https://www.mdpi.com/journal/cancers/special_issues/91X4P6MML3, in which 14 papers have been published in total.

Lung cancer is the leading cause of cancer-related death worldwide, with a 5-year survival rate of approximately 18%. Each year, more than 2 million people are diagnosed with lung cancer around the world, and most of them are diagnosed with locally advanced or metastatic disease. Therefore, early diagnosis is one of the key steps to improve and promote precision medicine for this disease.

Lung cancer management has changed in the last decade. State-of-the-art molecular pathology has allowed the development of more effective therapeutic strategies for this disease. However, there is still a long way to go before precision medicine is available for all, which will require further research into the molecular mechanisms underlying lung cancer and potential new druggable targets based on the molecular background of tumors. The current issue aims to increase our knowledge in order to achieve these goals.

We are pleased to invite both original research and review articles that highlight recent advances in this exciting field of research. We are looking for articles on the discovery of molecular insights and targeted therapies for use in preclinical in vitro and in vivo models and/or articles investigating their role in translation to clinical practice. We also welcome articles that cover other topics with the aim of improving or providing an alternative paradigm of precision medicine in lung cancer.

I look forward to receiving your contributions.

Dr. Sonia Molina-Pinelo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • non-small-cell lung cancer
  • small-cell lung cancer
  • biomarkers
  • oncogene-drive tumors
  • molecular mechanisms
  • targeted therapies
  • immunotherapy
  • precision medicine
  • preclinical models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 3150 KB  
Article
Molecular Links Between Smoking, COPD, and Lung Cancer: A DNA Methylation Perspective
by Camila Bernal Forigua, Litzy Gisella Bermúdez, Alejandra Cañas Arboleda, Rafael R. Ariza, Maria Teresa Roldán, Maria Teresa Morales, Daniel Mauricio González Cubides and Adriana Rojas
Cancers 2026, 18(8), 1273; https://doi.org/10.3390/cancers18081273 - 17 Apr 2026
Viewed by 661
Abstract
Background: DNA methylation alterations represent a key epigenetic mechanism linking environmental exposures to disease pathogenesis. The present study aimed to identify differentially methylated genes and shared biological processes associated with lung cancer (LuCa), chronic obstructive pulmonary disease (COPD) and tobacco exposure. Methods: A [...] Read more.
Background: DNA methylation alterations represent a key epigenetic mechanism linking environmental exposures to disease pathogenesis. The present study aimed to identify differentially methylated genes and shared biological processes associated with lung cancer (LuCa), chronic obstructive pulmonary disease (COPD) and tobacco exposure. Methods: A comprehensive literature search was performed in PubMed to identify studies evaluating DNA methylation in LuCa, COPD and smoking-related models. A total of 117 articles were selected, including 83 studies on lung cancer, 18 on COPD and 16 on smoking exposure. Genes exhibiting statistically significant methylation changes relative to controls were extracted from each study. To provide additional support for these findings, differential methylation signatures were further evaluated using The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) datasets. Functional and transcription factor motif enrichment analyses were subsequently conducted to identify shared biological pathways and regulatory mechanisms. Results: In total, 324 genes displaying altered methylation patterns across these conditions were identified. Seven tumor suppressor genes (CDKN2A, CDH13, MGMT, MIR137, DAPK1, RARB, and RASSF1A) consistently exhibited hypermethylation in both lung cancer and in association with smoking exposure. In addition, AHRR hypomethylation emerged as a shared epigenetic hallmark across all three conditions. TCGA-based analyses confirmed several of these methylation patterns and revealed subtype-specific methylation profiles associated with smoking history. Functional enrichment highlighted common biological processes and signaling pathways, particularly those related to transcriptional regulation, apoptosis and cancer-associated pathways. Conclusions: These results provide an integrative overview of shared DNA methylation alterations associated with smoking exposure, COPD, and lung cancer, and suggest potential DNA methylation candidates that may be relevant for future biomarker development and mechanistic studies. Full article
Show Figures

Figure 1

Back to TopTop